AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01178996
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks
Trial: NCT01408056
Drug: Timolol 0.5% Gel Forming Solution (GFS)
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day
Trial: NCT01408056
Drug: Mupirocin 2% Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application twice per day for 60 days
Trial: NCT03298542
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
Trial: NCT01653028
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02960997
Drug: Sirolimus, 2%
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02797067
Drug: Glycerin Suppository
RxNorm normalized name: Leader Pediatric Glycerin Suppository
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30min before ESWL
Trial: NCT03559920
Drug: Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
Trial: NCT03559920
Drug: Sedate using propofol.
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
Trial: NCT00002951
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04739865
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label
Trial: NCT02656615
Drug: abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
Trial: NCT02367066
Drug: AR-C165395XX
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of AR-C165395XX (tablets)
Trial: NCT01182766
Drug: Topiramate with brief behavioral enhancement therapy
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
Trial: NCT01221727
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
Trial: NCT01221727
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will receive two oral dose administrations of midazolam.
Trial: NCT03846167
Drug: Imaging Drug FluorThanatrace (FTT)
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
Trial: NCT00909233
Drug: Vardenafil, (Levitra, BAY38-9456)
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients under daily life treatment receiving Levitra according to local drug information.
Trial: NCT03675776
Drug: Rapastinel
RxNorm normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration).
Trial: NCT03684642
Drug: Efpeglenatide
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection; Route of administration: SC
Trial: NCT03684642
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: solution for injection; Route of administration: SC
Trial: NCT03684642
Drug: Background therapy Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
Trial: NCT02952937
Drug: GLA5PR GLARS-NF3 tablet 300mg
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A new formulation(3rd.) of Pregabalin CR tablet
Trial: NCT01082380
Drug: PF-02341066
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
Trial: NCT02856893
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib 60 or 40 mg daily until progression
Trial: NCT02856893
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg daily until progression
Trial: NCT00034749
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03332511
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 300mg twice-daily
Trial: NCT00001965
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03103061
Drug: Lexiscan
RxNorm normalized name: Lexiscan
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coronary vasodilator
Trial: NCT02270437
Drug: ropivacaine, fentanyl, adrenaline
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
Trial: NCT01981369
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous sedation with dexmedetomidine
Trial: NCT01981369
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with propofol
Trial: NCT00293488
Drug: polyamine analogue PG11047
RxNorm normalized name: POLOXAMINE 1304
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02744937
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin is continued by its regular dosing
Trial: NCT04048161
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is \< 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day.
Trial: NCT02952937
Drug: GLA5PR GLARS-NF1 tablet 300mg
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A new formulation(1st.) of Pregabalin CR tablet
Trial: NCT03278782
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03933735
Drug: TNB-383B
RxNorm normalized name: TNB-383B
DrugBank: TNB-383B (DB17268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Injection
Trial: NCT04048161
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20\~30mg/kg/day，BID. The concentration for MPA-AUC is 30\~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day.
Trial: NCT00617643
Drug: Nevirapine without dose escalation
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
Trial: NCT00617643
Drug: Nevirapine initiation with dose escalation
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
Trial: NCT02694809
Drug: Conjugated Estrogens/Bazedoxifene
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03860571
Drug: BT-11
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01711671
Drug: DKN-01 300 mg
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
Trial: NCT01711671
Drug: DKN-01 600 mg
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
Trial: NCT00415311
Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
RxNorm normalized name: Recombinant human mannose-binding lectin
DrugBank: Mannose (DB12907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
Trial: NCT02212561
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally on days 1,3,8,10,22 and 24 of each cycle
Trial: NCT02212561
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Trial: NCT02212561
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Trial: NCT00004861
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004861
Drug: tacedinaline
RxNorm normalized name: Tacedinaline
DrugBank: Tacedinaline (DB12291)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00334828
Drug: eritoran tetrasodium
DrugBank: Eritoran (DB04933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion at a total dose of 105 mg.
Trial: NCT00004161
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04529187
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
Trial: NCT04529187
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
Trial: NCT05313100
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
Trial: NCT00300079
Drug: brinzolamide 1.0%
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01056380
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, 500 mg with food twice daily for 5 days
Trial: NCT02972762
Drug: Diprivan
RxNorm normalized name: Diprivan
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
Trial: NCT00768469
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally, continuous, once daily.
Trial: NCT00768469
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV, on days 1, 8, 15 of 28 day cycle.
Trial: NCT04693026
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir 100 IV Infusion as a lyophilized powder
Trial: NCT04693026
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib oral tablet form
Trial: NCT04693026
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab IV Infusion
Trial: NCT03800810
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01372254
Drug: Transdermal Nicotine Patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
Trial: NCT03526874
Drug: Lidocaine 4% Topical Application Cream [LMX 4]
RxNorm normalized name: Lidocaine 4% Topical application Cream [LMX 4]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
Trial: NCT03526874
Drug: Lidocaine Hydrochloride 2 mg/mL Injectable Solution
RxNorm normalized name: lidocaine hydrochloride 2 MG/ML Injectable Solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.
Trial: NCT00047294
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00047294
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03451331
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
Trial: NCT03451331
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2
Trial: NCT03451331
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 4.5 (based on the Calvert formula)
Trial: NCT03451331
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m\^2
Trial: NCT02419469
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11.
Trial: NCT02419469
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
Trial: NCT02419469
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days.
Trial: NCT05862454
Drug: Magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium injection therapy
Trial: NCT02419469
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
Trial: NCT02419469
Drug: PEG asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3.
Trial: NCT02419469
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3.
Trial: NCT02419469
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3.
Trial: NCT02419469
Drug: Dexamethasone acetate
RxNorm normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days.
Trial: NCT02419469
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
Trial: NCT01682512
Drug: BI 695500
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00127257
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04404816
Drug: heliox
RxNorm normalized name: Helixate
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.